Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113759 · ClinicalTrials.gov registry record · NA
Blood Flow Restriction Following Hip Arthroscopy
A NA study of Femoral Acetabular Impingement and Labral Tear, Glenoid, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04113759 is a NA study of Femoral Acetabular Impingement and Labral Tear, Glenoid that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04113759, a NA study of Femoral Acetabular Impingement and Labral Tear, Glenoid, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.
Conditions Studied
Interventions
- BEHAVIORAL Blood Flow Restriction Rehabilitative Therapy
- BEHAVIORAL Sham BFR Rehabilitative Therapy
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2028-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04113759
The ClinicalTrials.gov registry entry for NCT04113759 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Femoral Acetabular Impingement appearing as the primary indexed condition, and to 2 interventions - of which Blood Flow Restriction Rehabilitative Therapy is the first listed.
NCT04113759 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04113759 about?
NCT04113759 is a clinical study titled "Blood Flow Restriction Following Hip Arthroscopy". This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will ...
What is the current status of trial NCT04113759?
This trial is currently recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2023-08-01. Estimated completion is 2028-01.
What conditions does trial NCT04113759 study?
This clinical trial studies the following conditions: Femoral Acetabular Impingement, Labral Tear, Glenoid.
What interventions are being tested in trial NCT04113759?
The interventions under investigation include: Blood Flow Restriction Rehabilitative Therapy (BEHAVIORAL), Sham BFR Rehabilitative Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT04113759?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04113759 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Femoral Acetabular Impingement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.